All publications can be found at this PubMed link


  • Tabet, A., Agarwal, Y., Stinson, J., Apra, C., Will, V., Manthey, M., Momin, N., Sheen, A., Murdock, M., Santollani, L., Tsai, L., Chiu, I., Lawler, S., Irvine, D. J., Wittrup, K. D., Anikeeva, P. (2022). Reprogramming brain immunosurveillance with engineering cytokines.
  • Wittrup, K. D., Kaufman, H. L., Schmidt, M. M., Irvine, D. J. (2022). Intratumorally anchored cytokine therapy. Expert Opin Drug Deliv, 2022 Jun 2:1-8.
  • Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., Spranger, S. (2022). Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022 Feb 8;55(2):308-323.e9.
  • Agarwal, Y., Milling, L. E., Chang, J. Y. H., Santollani, L., Sheen, A., Lutz, E. A., Tabet, A., Stinson, J., Ni, K., Rodrigues, K. A., Moyer, T. J., Melo, M. B., Irvine, D. J., Wittrup, K. D. (2022). Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat Biomed Eng 6, 129–143.
  • Kang, B. H., Lax, B. M., Wittrup, K. D. (2022). Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation. Methods Mol Biol. 2022;2491:29-62. doi: 10.1007/978-1-0716-2285-8_2
  • Momin, N., Palmeri, J.R., Lutz, E.A., Jailkhani, N., Mak, H., Tabet, A., Chinn, M. M., Kang, B. H., Spanoudaki, V., Hynes, R. O., Wittrup, K.D. (2022). Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nat Commun 13, 109.


  • Horton, B. L., Morgan, D. M., Momin, N., Zagorulya, M., Torres-Mejia, E., Bhandarkar, V., Wittrup, K. D., Love,  J. C., Spranger, S. (2021). Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol. 2021 Oct 29;6(64):eabi8800.
  • Kang, B. H., Momin, N., Moynihan, K. D., Silva, M., Li, Y., Irvine, D. J., & Wittrup, K. D. (2021). Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. PloS one16(4), e0248903.
  • Hu, G., Su, Y., Kang, B. H., Fan, Z., Dong, T., Brown, D. R., Cheah, J., Wittrup, K. D., & Chen, J. (2021). High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. Nature communications12(1), 773.
  • Tabet, A., Antonini, M., Sahasrabudhe, A., Park, J., Rosenfeld, D., Koehler, F., Yuk, H., Hanson, S., Stinson, J., Stok, M., Zhao, X., Wang, C., Anikeeva, P. (2021). Modular Integration of Hydrogel Neural Interfaces. ACS Central Science.


  • Orozco, J. J., Kenoyer, A. L., Lin, Y., O’Steen, S., Guel, R., Nartea, M. E., Hernandez, A. H., Hylarides, M. D., Fisher, D. R., Balkin, E. R., Hamlin, D. K., Wilbur, D. S., Orcutt, K. D., Wittrup, K. D., Green, D. J., Gopal, A. K., Till, B. G., Sandmaier, B., Press, O. W., & Pagel, J. M. (2020). Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular cancer therapeutics19(12), 2575–2584.
  • Mehta, N. K., Pradhan, R. V., Soleimany, A. P., Moynihan, K. D., Rothschilds, A. M., Momin, N., Rakhra, K., Mata-Fink, J., Bhatia, S. N., Wittrup, K. D., & Irvine, D. J. (2020). Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. Nature biomedical engineering4(6), 636–648.


  • Ma, L., Dichwalkar, T., Chang, J., Cossette, B., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., Kumari, S., Mehta, N. K., Abraham, W., Thai, N., Li, N., Wittrup, K. D., & Irvine, D. J. (2019). Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science (New York, N.Y.)365(6449), 162–168.
  • Momin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., & Wittrup, K. D. (2019). Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Science translational medicine11(498), eaaw2614.
  • Dréau, D., Moore, L. J., Wu, M., Roy, L. D., Dillion, L., Porter, T., Puri, R., Momin, N., Wittrup, K. D., & Mukherjee, P. (2019). Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in oncology9, 330.
  • Rothschilds, A., Tzeng, A., Mehta, N. K., Moynihan, K. D., Irvine, D. J., & Wittrup, K. D. (2019). Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. Oncoimmunology8(5), e1558678.
  • Rothschilds, A. M., & Wittrup, K. D. (2019). What, Why, Where, and When: Bringing Timing to Immuno-Oncology. Trends in immunology40(1), 12–21.


  • Kauke, MJ, Tisdale, AW, Kelly, RL, Braun, CJ, Hemann, MT, Wittrup, KD (2018). A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Mol. Cancer Ther.17,1773-1780.
  • Chen, TF, Li, KK, Zhu, EF, Opel, CF, Kauke, MJ, Kim, H, Atolia, E, Wittrup, KD (2018). Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types. J. Mol. Biol.430,1786-1798.
  • Angelini, A, Miyabe, Y, Newsted, D, Kwan, BH, Miyabe, C, Kelly, RL, Jamy, MN, Luster, AD, Wittrup, KD (2018). Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nat Commun9,1461.
  • Kelly, RL, Le, D, Zhao, J, Wittrup, KD (2018). Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. J. Mol. Biol.430,119-130.
  • Green, DJ, O’Steen, S, Lin, Y, Comstock, ML, Kenoyer, AL, Hamlin, DK, Wilbur, DS, Fisher, DR, Nartea, M, Hylarides, MD et al. (2018). CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood131,611-620.


  • Kelly, RL, Zhao, J, Le, D, Wittrup, KD (2017). Nonspecificity in a nonimmune human scFv repertoire. MAbs9,1029-1035.
  • Wittrup, KD (2017). Antitumor Antibodies Can Drive Therapeutic T Cell Responses. Trends Cancer3,615-620.
  • Kelly, RL, Geoghegan, JC, Feldman, J, Jain, T, Kauke, M, Le, D, Zhao, J, Wittrup, KD (2017). Chaperone proteins as single component reagents to assess antibody nonspecificity. MAbs9,1036-1040.
  • Kauke, MJ, Traxlmayr, MW, Parker, JA, Kiefer, JD, Knihtila, R, McGee, J, Verdine, G, Mattos, C, Wittrup, KD (2017). An engineered protein antagonist of K-Ras/B-Raf interaction. Sci Rep7,5831.
  • Cheal, SM, Fung, EK, Patel, M, Xu, H, Guo, HF, Zanzonico, PB, Monette, S, Wittrup, KD, Cheung, NV, Larson, SM et al. (2017). Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. J. Nucl. Med.58,1735-1742.
  • Chen, TF, Sazinsky, SL, Houde, D, DiLillo, DJ, Bird, J, Li, KK, Cheng, GT, Qiu, H, Engen, JR, Ravetch, JV et al. (2017). Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. J. Mol. Biol.429,2528-2541.
  • Yang, NJ, Kauke, MJ, Sun, F, Yang, LF, Maass, KF, Traxlmayr, MW, Yu, Y, Xu, Y, Langer, RS, Anderson, DG et al. (2017). Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Res.45,7602-7614.
  • Kwan, BH, Zhu, EF, Tzeng, A, Sugito, HR, Eltahir, AA, Ma, B, Delaney, MK, Murphy, PA, Kauke, MJ, Angelini, A et al. (2017). Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J. Exp. Med.214,1679-1690.
  • Smith, TT, Moffett, HF, Stephan, SB, Opel, CF, Dumigan, AG, Jiang, X, Pillarisetty, VG, Pillai, SPS, Wittrup, KD, Stephan, MT et al. (2017). Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J. Clin. Invest.127,2176-2191.
  • Jain, T, Sun, T, Durand, S, Hall, A, Houston, NR, Nett, JH, Sharkey, B, Bobrowicz, B, Caffry, I, Yu, Y et al. (2017). Biophysical properties of the clinical-stage antibody landscape. Proc. Natl. Acad. Sci. U.S.A.114,944-949.


  • Sharkey, B, Pudi, S, Wallace Moyer, I, Zhong, L, Prinz, B, Baruah, H, Lynaugh, H, Kumar, S, Wittrup, KD, Nett, JH et al. . Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. MAbs9,257-268.
  • Tzeng, A, Kauke, MJ, Zhu, EF, Moynihan, KD, Opel, CF, Yang, NJ, Mehta, N, Kelly, RL, Szeto, GL, Overwijk, WW et al. (2016). Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep17,2503-2511.
  • Green, DJ, Frayo, SL, Lin, Y, Hamlin, DK, Fisher, DR, Frost, SH, Kenoyer, AL, Hylarides, MD, Gopal, AK, Gooley, TA et al. (2016). Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Res.76,6669-6679.
  • Moynihan, KD, Opel, CF, Szeto, GL, Tzeng, A, Zhu, EF, Engreitz, JM, Williams, RT, Rakhra, K, Zhang, MH, Rothschilds, AM et al. (2016). Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med.22,1402-1410.
  • Kelly, RL, Yu, Y, Sun, T, Caffry, I, Lynaugh, H, Brown, M, Jain, T, Xu, Y, Wittrup, KD (2016). Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs8,1269-1275.
  • Traxlmayr, MW, Kiefer, JD, Srinivas, RR, Lobner, E, Tisdale, AW, Mehta, NK, Yang, NJ, Tidor, B, Wittrup, KD (2016). Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. J. Biol. Chem.291,22496-22508.
  • de Picciotto, S, Dickson, PM, Traxlmayr, MW, Marques, BS, Socher, E, Zhao, S, Cheung, S, Kiefer, JD, Wand, AJ, Griffith, LG et al. (2016). Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. J. Mol. Biol.428,4228-4241.
  • Singh, AP, Maass, KF, Betts, AM, Wittrup, KD, Kulkarni, C, King, LE, Khot, A, Shah, DK (2016). Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS J18,861-75.
  • Bornholdt, ZA, Turner, HL, Murin, CD, Li, W, Sok, D, Souders, CA, Piper, AE, Goff, A, Shamblin, JD, Wollen, SE et al. (2016). Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science351,1078-83.
  • Maass, KF, Kulkarni, C, Betts, AM, Wittrup, KD (2016). Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS J18,635-46.
  • Schütz, M, Batyuk, A, Klenk, C, Kummer, L, de Picciotto, S, Gülbakan, B, Wu, Y, Newby, GA, Zosel, F, Schöppe, J et al. (2016). Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools. J. Mol. Biol.428,1272-1289.
  • Cheal, SM, Xu, H, Guo, HF, Lee, SG, Punzalan, B, Chalasani, S, Fung, EK, Jungbluth, A, Zanzonico, PB, Carrasquillo, JA et al. (2016). Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur. J. Nucl. Med. Mol. Imaging43,925-37.


  • Maass, KF, Kulkarni, C, Quadir, MA, Hammond, PT, Betts, AM, Wittrup, KD (2015). A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. J Pharm Sci104,4409-4416.
  • Van Deventer, JA, Kelly, RL, Rajan, S, Wittrup, KD, Sidhu, SS (2015). A switchable yeast display/secretion system. Protein Eng. Des. Sel.28,317-25.
  • Angelini, A, Chen, TF, de Picciotto, S, Yang, NJ, Tzeng, A, Santos, MS, Van Deventer, JA, Traxlmayr, MW, Wittrup, KD (2015). Protein Engineering and Selection Using Yeast Surface Display. Methods Mol. Biol.1319,3-36.
  • Kelly, RL, Sun, T, Jain, T, Caffry, I, Yu, Y, Cao, Y, Lynaugh, H, Brown, M, Vásquez, M, Wittrup, KD et al. (2015). High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs7,770-7.
  • Yang, NJ, Liu, DV, Sklaviadis, D, Gui, DY, Vander Heiden, MG, Wittrup, KD (2015). Antibody-mediated neutralization of perfringolysin o for intracellular protein delivery. Mol. Pharm.12,1992-2000.
  • Zhu, EF, Gai, SA, Opel, CF, Kwan, BH, Surana, R, Mihm, MC, Kauke, MJ, Moynihan, KD, Angelini, A, Williams, RT et al. (2015). Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell27,489-501.
  • Tzeng, A, Kwan, BH, Opel, CF, Navaratna, T, Wittrup, KD (2015). Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc. Natl. Acad. Sci. U.S.A.112,3320-5.
  • Wang, S, Mata-Fink, J, Kriegsman, B, Hanson, M, Irvine, DJ, Eisen, HN, Burton, DR, Wittrup, KD, Kardar, M, Chakraborty, AK et al. (2015). Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell160,785-797.
  • Rouha, H, Badarau, A, Visram, ZC, Battles, MB, Prinz, B, Magyarics, Z, Nagy, G, Mirkina, I, Stulik, L, Zerbs, M et al. (2015). Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs7,243-54.


  • Paulus, GL, Nelson, JT, Lee, KY, Wang, QH, Reuel, NF, Grassbaugh, BR, Kruss, S, Landry, MP, Kang, JW, Vander Ende, E et al. (2014). A graphene-based physiometer array for the analysis of single biological cells. Sci Rep4,6865.
  • Yao, X, Williamson, C, Adalsteinsson, VA, D’Agostino, RS, Fitton, T, Smaroff, GG, William, RT, Wittrup, KD, Love, JC (2014). Tumor cells are dislodged into the pulmonary vein during lobectomy. J. Thorac. Cardiovasc. Surg.148,3224-31.e1-5.
  • Liu, DV, Yang, NJ, Wittrup, KD (2014). A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. Mol Ther Nucleic Acids3,e162.
  • de Picciotto, S, Imperiali, B, Griffith, LG, Wittrup, KD (2014). Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. Anal. Biochem.460,9-15.
  • Bak, SP, Barnkob, MS, Wittrup, KD, Chen, J (2013). CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate. Cancer Immunol Res1,393-401.
  • Yao, X, Choudhury, AD, Yamanaka, YJ, Adalsteinsson, VA, Gierahn, TM, Williamson, CA, Lamb, CR, Taplin, ME, Nakabayashi, M, Chabot, MS et al. (2014). Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb)6,388-98.
  • Van Deventer, JA, Wittrup, KD (2014). Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. Methods Mol. Biol.1131,151-81.


  • Schmidt, MM, Townson, SA, Andreucci, AJ, King, BM, Schirmer, EB, Murillo, AJ, Dombrowski, C, Tisdale, AW, Lowden, PA, Masci, AL et al. (2013). Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure21,1966-78.
  • Xu, Y, Roach, W, Sun, T, Jain, T, Prinz, B, Yu, TY, Torrey, J, Thomas, J, Bobrowicz, P, Vásquez, M et al. (2013). Addressing polyspecificity of antibodies selected from an in vitroyeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng. Des. Sel.26,663-70.
  • Adalsteinsson, VA, Tahirova, N, Tallapragada, N, Yao, X, Campion, L, Angelini, A, Douce, TB, Huang, C, Bowman, B, Williamson, CA et al. (2013). Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines. Integr Biol (Camb)5,1272-81.
  • Reuel, NF, Grassbaugh, B, Kruss, S, Mundy, JZ, Opel, C, Ogunniyi, AO, Egodage, K, Wahl, R, Helk, B, Zhang, J et al. (2013). Emergent properties of nanosensor arrays: applications for monitoring IgG affinity distributions, weakly affined hypermannosylation, and colony selection for biomanufacturing. ACS Nano7,7472-82.
  • Pirie, CM, Liu, DV, Wittrup, KD (2013). Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin. Mol. Cancer Ther.12,1774-82.
  • Yao, X, Labelle, M, Lamb, CR, Dugan, JM, Williamson, CA, Spencer, DR, Christ, KR, Keating, RO, Lee, WD, Paradis, GA et al. (2013). Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. Int. J. Cancer133,2925-33.
  • Su, X, Yang, N, Wittrup, KD, Irvine, DJ (2013). Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles. Biomacromolecules14,1093-102.
  • Kwong, B, Gai, SA, Elkhader, J, Wittrup, KD, Irvine, DJ (2013). Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res.73,1547-58.
  • Chen, TF, de Picciotto, S, Hackel, BJ, Wittrup, KD (2013). Engineering fibronectin-based binding proteins by yeast surface display. Meth. Enzymol.523,303-26.
  • Yazaki, PJ, Lee, B, Channappa, D, Cheung, CW, Crow, D, Chea, J, Poku, E, Li, L, Andersen, JT, Sandlie, I et al. (2013). A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng. Des. Sel.26,187-93.
  • Mata-Fink, J, Kriegsman, B, Yu, HX, Zhu, H, Hanson, MC, Irvine, DJ, Wittrup, KD (2013). Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J. Mol. Biol.425,444-56.


  • Yazaki, PJ, Lee, B, Channappa, D, Cheung, CW, Crow, D, Chea, J, Poku, E, Li, L, Andersen, JT, Sandlie, I et al. (2013). A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng. Des. Sel.26,187-93.
  • Mata-Fink, J, Kriegsman, B, Yu, HX, Zhu, H, Hanson, MC, Irvine, DJ, Wittrup, KD (2013). Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. J. Mol. Biol.425,444-56.
  • Bak, SP, Barnkob, MS, Bai, A, Higham, EM, Wittrup, KD, Chen, J (2012). Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J. Immunol.189,1708-16.
  • Spangler, JB, Manzari, MT, Rosalia, EK, Chen, TF, Wittrup, KD (2012). Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J. Mol. Biol.422,532-44.
  • Orcutt, KD, Rhoden, JJ, Ruiz-Yi, B, Frangioni, JV, Wittrup, KD (2012). Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol. Cancer Ther.11,1365-72.
  • Wittrup, KD, Verdine, GL (2012). Protein engineering for therapeutics, part B. Preface. Meth. Enzymol.503,xiii-xiv.
  • Wittrup, KD, Thurber, GM, Schmidt, MM, Rhoden, JJ (2012). Practical theoretic guidance for the design of tumor-targeting agents. Meth. Enzymol.503,255-68.
  • Wittrup, KD, Verdine, GL (2012). Protein engineering for therapeutics, Part A. Preface. Meth. Enzymol.502,xiii-xiv.
  • Hackel, BJ, Neil, JR, White, FM, Wittrup, KD (2012). Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng. Des. Sel.25,47-57.
  • Rhoden, JJ, Wittrup, KD (2012). Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci101,860-7.


  • Boersma, YL, Chao, G, Steiner, D, Wittrup, KD, Plückthun, A (2011). Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem.286,41273-85.
  • Schiefner, A, Chatwell, L, Körner, J, Neumaier, I, Colby, DW, Volkmer, R, Wittrup, KD, Skerra, A (2011). A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J. Mol. Biol.414,337-55.
  • Ackerman, ME, Lai, JI, Pastan, I, Wittrup, KD (2011). Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Eng. Des. Sel.24,845-53.
  • Orcutt, KD, Slusarczyk, AL, Cieslewicz, M, Ruiz-Yi, B, Bhushan, KR, Frangioni, JV, Wittrup, KD (2011). Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl. Med. Biol.38,223-33.
  • Pirie, CM, Hackel, BJ, Rosenblum, MG, Wittrup, KD (2011). Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J. Biol. Chem.286,4165-72.
  • Swers, JS, Yeung, YA, Wittrup, KD (2011). Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination. Mol. Biotechnol.47,57-69.


  • Orcutt, KD, Slusarczyk, AL, Cieslewicz, M, Ruiz-Yi, B, Bhushan, KR, Frangioni, JV, Wittrup, KD (2011). Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl. Med. Biol.38,223-33.
  • Pirie, CM, Hackel, BJ, Rosenblum, MG, Wittrup, KD (2011). Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J. Biol. Chem.286,4165-72.
  • Spangler, JB, Neil, JR, Abramovitch, S, Yarden, Y, White, FM, Lauffenburger, DA, Wittrup, KD (2010). Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl. Acad. Sci. U.S.A.107,13252-7.
  • Hackel, BJ, Ackerman, ME, Howland, SW, Wittrup, KD (2010). Stability and CDR composition biases enrich binder functionality landscapes. J. Mol. Biol.401,84-96.
  • Higham, EM, Shen, CH, Wittrup, KD, Chen, J (2010). Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J. Immunol.184,5954-8.
  • Higham, EM, Wittrup, KD, Chen, J (2010). Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J. Immunol.184,3394-400.
  • Hackel, BJ, Wittrup, KD (2010). The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng. Des. Sel.23,211-9.
  • Orcutt, KD, Ackerman, ME, Cieslewicz, M, Quiroz, E, Slusarczyk, AL, Frangioni, JV, Wittrup, KD (2010). A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel.23,221-8.


  • Orcutt, KD, Ackerman, ME, Cieslewicz, M, Quiroz, E, Slusarczyk, AL, Frangioni, JV, Wittrup, KD (2010). A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel.23,221-8.
  • Schmidt, MM, Wittrup, KD (2009). A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther.8,2861-71.
  • Liu, DV, Maier, LM, Hafler, DA, Wittrup, KD . Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J. Immunother.32,887-94.
  • Tasumi, S, Velikovsky, CA, Xu, G, Gai, SA, Wittrup, KD, Flajnik, MF, Mariuzza, RA, Pancer, Z (2009). High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A.106,12891-6.
  • Rakestraw, JA, Sazinsky, SL, Piatesi, A, Antipov, E, Wittrup, KD (2009). Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnol. Bioeng.103,1192-201.
  • Ackerman, M, Levary, D, Tobon, G, Hackel, B, Orcutt, KD, Wittrup, KD . Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnol. Prog.25,774-83.
  • Maier, LM, Anderson, DE, Severson, CA, Baecher-Allan, C, Healy, B, Liu, DV, Wittrup, KD, De Jager, PL, Hafler, DA (2009). Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol.182,1541-7.


  • Sazinsky, SL, Ott, RG, Silver, NW, Tidor, B, Ravetch, JV, Wittrup, KD (2008). Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U.S.A.105,20167-72.
  • Antipov, E, Cho, AE, Wittrup, KD, Klibanov, AM (2008). Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proc. Natl. Acad. Sci. U.S.A.105,17694-9.
  • Bai, A, Higham, E, Eisen, HN, Wittrup, KD, Chen, J (2008). Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. U.S.A.105,13003-8.
  • Ackerman, ME, Pawlowski, D, Wittrup, KD (2008). Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol. Cancer Ther.7,2233-40.
  • Hackel, BJ, Kapila, A, Wittrup, KD (2008). Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J. Mol. Biol.381,1238-52.
  • Howland, SW, Tsuji, T, Gnjatic, S, Ritter, G, Old, LJ, Wittrup, KD (2008). Inducing efficient cross-priming using antigen-coated yeast particles. J. Immunother.31,607-19.
  • Thurber, GM, Schmidt, MM, Wittrup, KD (2008). Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev.60,1421-34.
  • Thurber, GM, Wittrup, KD (2008). Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res.68,3334-41.
  • Howarth, M, Liu, W, Puthenveetil, S, Zheng, Y, Marshall, LF, Schmidt, MM, Wittrup, KD, Bawendi, MG, Ting, AY (2008). Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat. Methods5,397-9.
  • Schmidt, MM, Thurber, GM, Wittrup, KD (2008). Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother.57,1879-90.
  • Ackerman, ME, Chalouni, C, Schmidt, MM, Raman, VV, Ritter, G, Old, LJ, Mellman, I, Wittrup, KD (2008). A33 antigen displays persistent surface expression. Cancer Immunol. Immunother.57,1017-27.
  • Howland, SW, Wittrup, KD (2008). Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J. Immunol.180,1576-83.
  • Thurber, GM, Schmidt, MM, Wittrup, KD (2008). Factors determining antibody distribution in tumors. Trends Pharmacol. Sci.29,57-61.


  • Yeung, YA, Finney, AH, Koyrakh, IA, Lebowitz, MS, Ghanbari, HA, Wands, JR, Wittrup, KD (2007). Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase. Hum Antibodies16,163-76.
  • Lipovsek, D, Antipov, E, Armstrong, KA, Olsen, MJ, Klibanov, AM, Tidor, B, Wittrup, KD (2007). Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. Chem. Biol.14,1176-85.
  • Lippow, SM, Wittrup, KD, Tidor, B (2007). Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol.25,1171-6.
  • Gai, SA, Wittrup, KD (2007). Yeast surface display for protein engineering and characterization. Curr. Opin. Struct. Biol.17,467-73.
  • Campbell, CJ, Wittrup, KD (2007). Protein technologies. Curr. Opin. Biotechnol.18,293-4.
  • Thurber, GM, Zajic, SC, Wittrup, KD (2007). Theoretic criteria for antibody penetration into solid tumors and micrometastases. J. Nucl. Med.48,995-9.
  • Lipovsek, D, Lippow, SM, Hackel, BJ, Gregson, MW, Cheng, P, Kapila, A, Wittrup, KD (2007). Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J. Mol. Biol.368,1024-41.
  • Krauland, EM, Peelle, BR, Wittrup, KD, Belcher, AM (2007). Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. Biotechnol. Bioeng.97,1009-20.


  • Chao, G, Lau, WL, Hackel, BJ, Sazinsky, SL, Lippow, SM, Wittrup, KD (2006). Isolating and engineering human antibodies using yeast surface display. Nat Protoc1,755-68.
  • Swers, JS, Widom, A, Phan, U, Springer, TA, Wittrup, KD (2006). A high affinity human antibody antagonist of P-selectin mediated rolling. Biochem. Biophys. Res. Commun.350,508-13.
  • Rakestraw, JA, Baskaran, AR, Wittrup, KD . A flow cytometric assay for screening improved heterologous protein secretion in yeast. Biotechnol. Prog.22,1200-8.
  • Cochran, JR, Kim, YS, Lippow, SM, Rao, B, Wittrup, KD (2006). Improved mutants from directed evolution are biased to orthologous substitutions. Protein Eng. Des. Sel.19,245-53.
  • Colby, DW, Cassady, JP, Lin, GC, Ingram, VM, Wittrup, KD (2006). Stochastic kinetics of intracellular huntingtin aggregate formation. Nat. Chem. Biol.2,319-23.
  • Piatesi, A, Howland, SW, Rakestraw, JA, Renner, C, Robson, N, Cebon, J, Maraskovsky, E, Ritter, G, Old, L, Wittrup, KD et al. (2006). Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. Protein Expr. Purif.48,232-42.
  • Sivasubramanian, A, Chao, G, Pressler, HM, Wittrup, KD, Gray, JJ (2006). Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure14,401-14.
  • Midelfort, KS, Wittrup, KD (2006). Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. Protein Sci.15,324-34.
  • Kim, YS, Bhandari, R, Cochran, JR, Kuriyan, J, Wittrup, KD (2006). Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins62,1026-35.
  • Rakestraw, A, Wittrup, KD (2006). Contrasting secretory processing of simultaneously expressed heterologous proteins in Saccharomyces cerevisiae. Biotechnol. Bioeng.93,896-905.


  • Peelle, BR, Krauland, EM, Wittrup, KD, Belcher, AM (2005). Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. Acta Biomater1,145-54.
  • Rao, BM, Driver, I, Lauffenburger, DA, Wittrup, KD (2005). High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry44,10696-701.
  • Peelle, BR, Krauland, EM, Wittrup, KD, Belcher, AM (2005). Design criteria for engineering inorganic material-specific peptides. Langmuir21,6929-33.
  • Rao, BM, Lauffenburger, DA, Wittrup, KD (2005). Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol.23,191-4.


  • Colby, DW, Chu, Y, Cassady, JP, Duennwald, M, Zazulak, H, Webster, JM, Messer, A, Lindquist, S, Ingram, VM, Wittrup, KD et al. (2004). Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U.S.A.101,17616-21.
  • Midelfort, KS, Hernandez, HH, Lippow, SM, Tidor, B, Drennan, CL, Wittrup, KD (2004). Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J. Mol. Biol.343,685-701.
  • Rao, BM, Driver, I, Lauffenburger, DA, Wittrup, KD (2004). Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol. Pharmacol.66,864-9.
  • Colby, DW, Garg, P, Holden, T, Chao, G, Webster, JM, Messer, A, Ingram, VM, Wittrup, KD (2004). Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol.342,901-12.
  • Chao, G, Cochran, JR, Wittrup, KD (2004). Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J. Mol. Biol.342,539-50.
  • Colby, DW, Kellogg, BA, Graff, CP, Yeung, YA, Swers, JS, Wittrup, KD (2004). Engineering antibody affinity by yeast surface display. Meth. Enzymol.388,348-58.
  • Graff, CP, Chester, K, Begent, R, Wittrup, KD (2004). Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng. Des. Sel.17,293-304.
  • Cochran, JR, Kim, YS, Olsen, MJ, Bhandari, R, Wittrup, KD (2004). Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J. Immunol. Methods287,147-58.
  • Johns, TG, Adams, TE, Cochran, JR, Hall, NE, Hoyne, PA, Olsen, MJ, Kim, YS, Rothacker, J, Nice, EC, Walker, F et al. (2004). Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J. Biol. Chem.279,30375-84.
  • Swers, JS, Kellogg, BA, Wittrup, KD (2004). Shuffled antibody libraries created by in vivohomologous recombination and yeast surface display. Nucleic Acids Res.32,e36.
  • Coughlan, CM, Walker, JL, Cochran, JC, Wittrup, KD, Brodsky, JL (2004). Degradation of mutated bovine pancreatic trypsin inhibitor in the yeast vacuole suggests post-endoplasmic reticulum protein quality control. J. Biol. Chem.279,15289-97.
  • Grovender, EA, Kellogg, B, Singh, J, Blom, D, Ploegh, H, Wittrup, KD, Langer, RS, Ameer, GA (2004). Single-chain antibody fragment-based adsorbent for the extracorporeal removal of beta2-microglobulin. Kidney Int.65,310-22.
  • Mohr L, Yeung A, Aloman C, Wittrup D, Wands JR. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology. 127(5 Suppl 2):S225-31, 2004.


  • Rao, BM, Girvin, AT, Ciardelli, T, Lauffenburger, DA, Wittrup, KD (2003). Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng.16,1081-7.
  • Bhatia, SK, Swers, JS, Camphausen, RT, Wittrup, KD, Hammer, DA . Rolling adhesion kinematics of yeast engineered to express selectins. Biotechnol. Prog.19,1033-7.
  • Orr, BA, Carr, LM, Wittrup, KD, Roy, EJ, Kranz, DM . Rapid method for measuring ScFv thermal stability by yeast surface display. Biotechnol. Prog.19,631-8.
  • Graff, CP, Wittrup, KD (2003). Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res.63,1288-96.
  • Feldhaus, MJ, Siegel, RW, Opresko, LK, Coleman, JR, Feldhaus, JM, Yeung, YA, Cochran, JR, Heinzelman, P, Colby, D, Swers, J et al. (2003). Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol.21,163-70.


  • Reardon, KF, Lee, KH, Wittrup, KD, Hatzimanikatis, V (2002). Jay Bailey as mentor–the students’ perspective. Biotechnol. Bioeng.79,484-9.
  • Yeung, YA, Wittrup, KD . Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol. Prog.18,212-20.


  • Reardon, KF, Lee, KH, Wittrup, KD, Hatzimanikatis, V (2002). Jay Bailey as mentor–the students’ perspective. Biotechnol. Bioeng.79,484-9.
  • Yeung, YA, Wittrup, KD . Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol. Prog.18,212-20.

2000 and earlier

  • Wittrup, KD (2001). Protein engineering by cell-surface display. Curr. Opin. Biotechnol.12,395-9.
  • Kieke, MC, Sundberg, E, Shusta, EV, Mariuzza, RA, Wittrup, KD, Kranz, DM (2001). High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. J. Mol. Biol.307,1305-15.
  • Boder, ET, Wittrup, KD (2000). Yeast surface display for directed evolution of protein expression, affinity, and stability. Meth. Enzymol.328,430-44.
  • Wittrup, KD (2000). The single cell as a microplate well. Nat. Biotechnol.18,1039-40.
  • Boder, ET, Midelfort, KS, Wittrup, KD (2000). Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. U.S.A.97,10701-5.
  • Shusta, EV, Holler, PD, Kieke, MC, Kranz, DM, Wittrup, KD (2000). Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol.18,754-9.
  • Boder, ET, Wittrup, KD . Optimal screening of surface-displayed polypeptide libraries. Biotechnol. Prog.14,55-62.
  • Holler, PD, Holman, PO, Shusta, EV, O’Herrin, S, Wittrup, KD, Kranz, DM (2000). In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. U.S.A.97,5387-92.
  • Bannister, SJ, Wittrup, KD (2000). Glutathione excretion in response to heterologous protein secretion in Saccharomyces cerevisiae. Biotechnol. Bioeng.68,389-95.
  • VanAntwerp, JJ, Wittrup, KD . Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol. Prog.16,31-7.
  • Woycechowsky, KJ, Wittrup, KD, Raines, RT (1999). A small-molecule catalyst of protein folding in vitro and in vivo. Chem. Biol.6,871-9.
  • Wittrup, KD (1999). Phage on display. Trends Biotechnol.17,423-4.
  • Shusta, EV, Kieke, MC, Parke, E, Kranz, DM, Wittrup, KD (1999). Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J. Mol. Biol.292,949-56.
  • Becker, F, Block-Alper, L, Nakamura, G, Harada, J, Wittrup, KD, Meyer, DI (1999). Expression of the 180-kD ribosome receptor induces membrane proliferation and increased secretory activity in yeast. J. Cell Biol.146,273-84.
  • Kieke, MC, Shusta, EV, Boder, ET, Teyton, L, Wittrup, KD, Kranz, DM (1999). Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl. Acad. Sci. U.S.A.96,5651-6.
  • Shusta, EV, VanAntwerp, J, Wittrup, KD (1999). Biosynthetic polypeptide libraries. Curr. Opin. Biotechnol.10,117-22.
  • Arnold, CE, Parekh, RN, Yang, W, Wittrup, KD (1998). Leader peptide efficiency correlates with signal recognition particle dependence in Saccharomyces cerevisiae. Biotechnol. Bioeng.59,286-93.
  • VanAntwerp, JJ, Wittrup, KD (1998). Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant. J. Mol. Recognit.11,10-3.
  • Cho, BK, Kieke, MC, Boder, ET, Wittrup, KD, Kranz, DM (1998). A yeast surface display system for the discovery of ligands that trigger cell activation. J. Immunol. Methods220,179-88.
  • Kowalski, JM, Kelly, RM, Konisky, J, Clark, DS, Wittrup, KD (1998). Purification and functional characterization of a chaperone from Methanococcus jannaschii. Syst. Appl. Microbiol.21,173-8.
  • Shusta, EV, Raines, RT, Plückthun, A, Wittrup, KD (1998). Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nat. Biotechnol.16,773-7.
  • Kowalski, JM, Parekh, RN, Mao, J, Wittrup, KD (1998). Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control. J. Biol. Chem.273,19453-8.
  • Kieke, MC, Cho, BK, Boder, ET, Kranz, DM, Wittrup, KD (1997). Isolation of anti-T cell receptor scFv mutants by yeast surface display. Protein Eng.10,1303-10.
  • Kowalski, JM, Parekh, RN, Wittrup, KD (1998). Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. Biochemistry37,1264-73.
  • Boder, ET, Wittrup, KD (1997). Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol.15,553-7.
  • Parekh, RN, Wittrup, KD . Expression level tuning for optimal heterologous protein secretion in Saccharomyces cerevisiae. Biotechnol. Prog.13,117-22.
  • Zabriskie, DW, Wittrup, KD (1996). Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: II. Biotechnol. Bioeng.52,183.
  • Zabriskie, DW, Wittrup, KD (1996). Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: I. Biotechnol. Bioeng.52,1-2.
  • Robinson, AS, Bockhaus, JA, Voegler, AC, Wittrup, KD (1996). Reduction of BiP levels decreases heterologous protein secretion in Saccharomyces cerevisiae. J. Biol. Chem.271,10017-22.
  • Parekh, RN, Shaw, MR, Wittrup, KD . An integrating vector for tunable, high copy, stable integration into the dispersed Ty delta sites of Saccharomyces cerevisiae. Biotechnol. Prog.12,16-21.
  • Wittrup, KD (1995). Disulfide bond formation and eukaryotic secretory productivity. Curr. Opin. Biotechnol.6,203-8.
  • Robinson, AS, Wittrup, KD . Constitutive overexpression of secreted heterologous proteins decreases extractable BiP and protein disulfide isomerase levels in Saccharomyces cerevisiae. Biotechnol. Prog.11,171-7.
  • Arnold, CE, Wittrup, KD (1994). The stress response to loss of signal recognition particle function in Saccharomyces cerevisiae. J. Biol. Chem.269,30412-8.
  • Wittrup, KD, Robinson, AS, Parekh, RN, Forrester, KJ (1994). Existence of an optimum expression level for secretion of foreign proteins in yeast. Ann. N. Y. Acad. Sci.745,321-30.
  • Wittrup, KD, Westerman, RJ, Desai, R (1994). Fluorescence array detector for large-field quantitative fluorescence cytometry. Cytometry16,206-13.
  • Robinson, AS, Hines, V, Wittrup, KD (1994). Protein disulfide isomerase overexpression increases secretion of foreign proteins in Saccharomyces cerevisiae. Biotechnology (N.Y.)12,381-4.
  • Wittrup, KD, Weber, AL, Tsai, P (1993). Microencapsulation selection for isolation of yeast mutants with increased secretion of Aspergillus awamori glucoamylase. Biotechnol. Bioeng.42,351-6.
  • Shaw, MR, Schiek, R, Wittrup, KD . Stochastic stimulation of 2 mu multicopy plasmid amplification in yeast. Biotechnol. Prog.9,160-5.
  • Wittrup, KD, Bailey, JE (1991). Comments on a segregated model of recombinant cultures: authors’ reply. Biotechnol. Bioeng.38,1364-5.
  • Wittrup, KD, Bailey, JE, Ratzkin, B, Patel, A (1990). Propagation of an amplifiable recombinant plasmid in Saccharomyces cerevisiae: flow cytometry studies and segregated modeling. Biotechnol. Bioeng.35,565-77.
  • Wittrup, KD, Bailey, JE (1990). Mathematical modeling of a single-cell enzyme assay. Biotechnol. Bioeng.35,525-32.
  • Meilhoc, E, Wittrup, KD, Bailey, JE (1989). Application of flow cytometric measurement of surface IgG in kinetic analysis of monoclonal antibody synthesis and secretion by murine hybridoma cells. J. Immunol. Methods121,167-74.
  • Budd, ME, Wittrup, KD, Bailey, JE, Campbell, JL (1989). DNA polymerase I is required for premeiotic DNA replication and sporulation but not for X-ray repair in Saccharomyces cerevisiae. Mol. Cell. Biol.9,365-76.
  • Wittrup, KD, Bailey, JE (1988). A single-cell assay of beta-galactosidase activity in Saccharomyces cerevisiae. Cytometry9,394-404.
  • Wittrup, KD, Bailey, JE (1988). A segregated model of recombinant multicopy plasmid propagation. Biotechnol. Bioeng.31,304-10.
  • Wittrup, KD, Bailey, JE (1988). A mathematical model of recombinational amplification of the 2 mu plasmid in the yeast Saccharomyces cerevisiae. J. Theor. Biol.130,481-92.